Memantine effect on patients with schizophrenia

Phase 1

• Conditions: Schizophrenia.; Schizophrenia

• Registration Number: IRCT20190606043827N1
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Schizophrenia according to DSM-IV criteria
Age 18 to 50 years
Receiving common drugs for schizophrenia for at least 3 months before the start of the study (Patients within 3 months of the previous 3 month antipsychotic with a constant dose of 300 to 1000 mg of chlorpromazine (except for clozapine) and a fixed dose of anticholinergic drug of 4 to 8 mg TG Phenidyl)
Mental Status Mini Test Score (MMSE) Between 18 and 24

Exclusion Criteria

Dependence and drug addiction
smoking
History of trauma to the head
History of seizure
Severe liver and kidney function disorders
Severe neurological disorders
Depression
Receiving drugs that affect cognitive symptoms

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Grade Severity of Positive and Negative Symptoms of Schizophrenia. Timepoint: Measure the mean score of severity of positive and negative symptoms of schizophrenia from baseline, 6th week and 12th week after drug and placebo study. Method of measurement: Questionnaire on the severity of positive and negative symptoms of schizophrenia.;Hamilton Depression Scale Score. Timepoint: Measurement of mean Hamilton Depression Rating Scale from baseline, 6th and 12th week after drug and placebo study. Method of measurement: Hamilton Depression Scale Questionnaire.;Adult Wechsler Memory Test Score. Timepoint: Measurement of mean Wechsler Adult Memory Test score from baseline, 6th week and 12th week after drug and placebo study. Method of measurement: Adult Wechsler memory test.